Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-AnalysisShixue Chen, Yi Hu, Xuan Zheng et al.|Frontiers in Oncology|2021Cited by 125
Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint InhibitorsZhibo Zhang, Jinliang Wang|Frontiers in Immunology|2020Cited by 54